scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

An intra-individual randomised controlled study to evaluate the efficacy and tolerance of the product RV4421 A BS0042 in association with a moderately potent topical corticosteroid in adults with atopic dermatitis

Dermatology Phase II Completed October 2014 July 2015

Analgesic profile of 3 new Ibuprofen lozenges (V0498TA01A 15mg, 25mg,

Central Nervous System Phase II Completed February 2012 November 2012

A randomised, double blind, controlled, multicentre study in infants with infantile hemangioma to compare propranolol gel to placebo

Dermatology Phase II Completed February 10, 2012 May 09, 2013

Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study

Cardiovascular Phase II Completed October 2009 May 2010

The effect of Minalcipran 100mg BID on sensitivity to stimulus-evoked pain in patients with Fibromyalgia : a FMRI neuroimaging study

Central Nervous System Phase II Completed October 2005 April 2007

Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy

Oncology Phase II Completed October 2015 October 2018

Analysis of the sensory profile of two new transdermal patches (V0116TD07AF019 and V0116TD07AF020) 21 mg/24h versus a reference transdermal patch (NICOTINELL TTS) 21 mg/24h

Dermatology Phase II Completed 2007 February 2008

Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects

Dermatology Phase II Completed 2008 April 2009

Assessment of the efficacy of a new formulation of minoxidil (DC120) on hair growth, in a minizone model in androgenetic alopecia in men.

Dermatology Phase II Completed August 2015 April 2016

Effects of TANGANIL (three 500 mg tablets twice daily) on postural disturbances in the elderly

Central Nervous System Phase II Completed June 2008 October 2008

A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines

Oncology Phase II Completed September 2004 June 2007

Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma

Respiratory Phase II Completed September 2013 April 2014

Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups

Dermatology Phase II Completed April 28, 2005 May 08, 2006

Effect of V0251 in acute vertigo. A randomized double blind placebo conrolled study

Central Nervous System Phase II Completed June 2012 April 2013

Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group

Vascular Phase II Completed December 2009 November 2010

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure

Cardiovascular Phase II Completed May 2013 June 2017

Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder

Urology Phase II Completed July 2011 October 2011

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides

Blood Disorders Phase II Completed April 2008 September 2008

Evaluation Of The Rate Of Pathological Complete Response (pCR) For Neoadjuvant Chemoradiotherapy (CT-RT) And For Chemotherapy (CT) Alone in Locally Advanced Non Small Cell Lung Cancer (LA-NSCLC): A Randomized Phase II trial

Oncology Phase II Completed June 2007 December 2007

Efficacy and safety of 8% Clobetasol nail lacquer formulation versus vehicle in nail psoriasis

Dermatology Phase II Completed 2006 November 2007

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

SPONSOR: PFIZER

Breast cancer 

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

SPONSOR: ATARA